NCT04084444View on ClinicalTrials.gov

Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

December 25, 2019

Primary Completion Date

July 5, 2022

Study Completion Date

July 5, 2022

Conditions
Chronic Abnormal Immune Activation in HIV/AIDS
Interventions
DRUG

T8 tablet 0.5mg

Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.

DRUG

T8 tablet 1mg

Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.

DRUG

Placebo

Blank control.

Trial Locations (9)

100032

Peking Union Medical College Hospital, Beijing

310023

Xixi Hospital of Hangzhou, Hangzhou

650399

Yun Provincial Infectious Disease Hospital, Kunming

Unknown

Beijing Dita Hospital, Capital Medical University, Beijing

Beijing You An Hospital, Capital Medical University, Beijing

The First Hospital of Changsha, Changsha

The Second Hospital of Nanjing, Nanjing

The First Affiliated Hospital, Zhejiang University, Hangzhou

Tianjin Second People's Hospital, Tianjin

All Listed Sponsors
lead

Shanghai Pharmaceuticals Holding Co., Ltd

INDUSTRY

NCT04084444 - Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS Patients | Biotech Hunter | Biotech Hunter